Peter Hotez, a virologist and dean of the National School of Tropical Medicine at Baylor College of Medicine, stated it was not clear if the problem was variant-specific or the vaccines inability to produce high levels of reducing the effects of antibodies.Since starting out in 2000, Tuebingen-based CureVac has actually focused on so-called messenger RNA (mRNA) innovation, which is also behind the success of BioNTech (22UAy. DE) and partner Pfizer (PFE.N) as well as Moderna (MRNA.O), whose vaccines have actually shown more than 90% reliable in avoiding illness.Prior to the development of the highly efficient vaccines, the U.S. Food and Drug Administration had targeted at least 50% effectiveness, which CureVac has fallen brief of in the interim analysis. The World Health Organization had stated it was looking for at least 70% efficacy.While late-stage trials of the BioNTech/Pfizer and Moderna vaccines were performed when the initial variation of the virus was dominant, real-world information has so far suggested just somewhat weaker defense versus the new variants.CureVac, which is backed by investors Dietmar Hopp, the Gates Foundation and GlaxoSmithKline (GSK.L), as well as the German federal government, had intended to produce up to 300 million doses of the vaccine in 2021 and up to 1 billion dosages in 2022.
Modifying by Chris ReeseOur Standards: The Thomson Reuters Trust Principles.

Peter Hotez, a virologist and dean of the National School of Tropical Medicine at Baylor College of Medicine, stated it was not clear if the concern was variant-specific or the vaccines failure to produce high levels of neutralizing antibodies.Since starting out in 2000, Tuebingen-based CureVac has focused on so-called messenger RNA (mRNA) technology, which is also behind the success of BioNTech (22UAy. DE) and partner Pfizer (PFE.N) as well as Moderna (MRNA.O), whose vaccines have shown more than 90% effective in avoiding illness.Prior to the development of the highly reliable vaccines, the U.S. Food and Drug Administration had targeted at least 50% effectiveness, which CureVac has fallen brief of in the interim analysis. The World Health Organization had stated it was looking for at least 70% efficacy.While late-stage trials of the BioNTech/Pfizer and Moderna vaccines were performed when the original version of the virus was dominant, real-world information has actually so far suggested just rather weaker defense against the new variants.CureVac, which is backed by investors Dietmar Hopp, the Gates Foundation and GlaxoSmithKline (GSK.L), as well as the German federal government, had actually intended to produce up to 300 million dosages of the vaccine in 2021 and up to 1 billion doses in 2022.